Literature DB >> 8869303

Cholangiocarcinoma in patients with opisthorchiasis.

P Watanapa1.   

Abstract

Cholangiocarcinoma is very common in areas endemic for the liver fluke Opisthorchis viverrini. Survival after surgical treatment of cholangiocarcinoma associated with opisthorchiasis was studied prospectively in 30 patients, all of whom resided in an endemic area. The median age was 52 (range 32-69) years and twenty-five patients were men. Seven patients had their tumours removed, four with concomitant liver resection. Twenty-two patients underwent palliative biliary bypass procedures to a segmental duct. Laparotomy with biopsy of metastatic lesions was undertaken in one patient with multiple lymph node metastases and peritoneal seedlings. No patient received postoperative chemotherapy or radiation treatment. Patients were followed for 2 years or until death. The 1-year survival rate after tumour resection was 86 per cent and the 2-year survival rate 43 per cent. After palliative procedures the 1-year survival rate was 26 per cent; no patient reached 2 years and the median survival time was 8 months. Survival after surgical treatment of cholangiocarcinoma in patients with opisthorchiasis is broadly similar to that reported for cholangiocarcinoma without liver fluke infestation.

Entities:  

Mesh:

Year:  1996        PMID: 8869303     DOI: 10.1002/bjs.1800830809

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

1.  Update on Hepatobiliary and Pulmonary Flukes.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

3.  Detection of salivary antibodies to crude antigens of Opisthorchis viverrini in opisthorchiasis and cholangiocarcinoma patients.

Authors:  Ponlatham Chaiyarit; Paiboon Sithithaworn; Chanitra Thuwajit; Puangrat Yongvanit
Journal:  Clin Oral Investig       Date:  2010-05-06       Impact factor: 3.573

4.  CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.

Authors:  Rosa Coelho; Marco Silva; Eduardo Rodrigues-Pinto; Hélder Cardoso; Susana Lopes; Pedro Pereira; Filipe Vilas-Boas; João Santos-Antunes; José Costa-Maia; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2017-02-23

5.  Genetic comparison of liver flukes, Clonorchis sinensis and Opisthorchis viverrini, based on rDNA and mtDNA gene sequences.

Authors:  Gab-Man Park
Journal:  Parasitol Res       Date:  2006-08-11       Impact factor: 2.289

Review 6.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27

7.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

8.  Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma.

Authors:  Prachya Kongtawelert; Pisit Tangkijvanich; Siriwan Ong-Chai; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 9.  Management of perihilar cholangiocarcinoma in the era of multimodal therapy.

Authors:  Vicente Valero; David Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-08       Impact factor: 3.869

10.  Prognostic value of DNA alterations on chromosome 17p13.2 for intrahepatic cholangiocarcinoma.

Authors:  Ubol Chuensumran; Sopit Wongkham; Chawalit Pairojkul; Siri Chauin; Songsak Petmitr
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.